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Abstract
Alzheimer’s disease (AD) is a complex disorder with a clear genetic component. Three genes have been identified as the cause of early
onset familial AD (EOAD). The most common form of the disease, late onset Alzheimer’s disease (LOAD), is, however, a sporadic one
presenting itself in later stages of life. The genetic component of this late onset form of AD has been the target of a large number of studies,
because only one genetic risk factor (APOE4) has been consistently associated with the disease. However, technological advances allow new
approaches in the study of complex disorders. In this review, we discuss the new results produced by genome wide association studies, in
light of the current knowledge of the complexity of AD genetics.
Published by Elsevier Inc.
www.elsevier.com/locate/neuaging1. Introduction
Historically, Alzheimer’s disease (AD) is the most com-
mon cause of dementia. It is a progressive neurodegenera-
tive disorder with an insidious onset, which typically ap-
pears in older individuals, but may affect people as early as
the third decade of life (Rademakers et al., 2003; Rogaeva,
2002). The genetics of Alzheimer’s disease is complex and
heterogeneous. Most cases are “sporadic” with no apparent
familial recurrence of the disease. However, a small per-
centage of AD cases (1–2% of all cases) have an early onset
(EOAD), with symptoms appearing before 65 years of age.
In these patients, the disease commonly aggregates within
families and typically presents an autosomal dominant pat-
tern of inheritance. Mutations in three genes are known to
account for this early onset, familial type of the disease:
amyloid precursor protein gene (APP), presenilin 1 gene
(PSEN1) and presenilin 2 gene (PSEN2) (Rogaeva, 2002).
* Corresponding author at. Tel.: 301 435 8866; fax: 301 451 7295.
E-mail address: portalegrer@nia.nih.gov (R.J. Guerreiro).
0197-4580/$ – see front matter Published by Elsevier Inc.
doi:10.1016/j.neurobiolaging.2010.03.025In fact, early-onset autosomal dominant disease with age of
onset younger than 60 years, seems to be completely ex-
plained by pathogenic mutations in these three genes.
The most common, late onset and sporadic form of the
disease remains mostly a genetic conundrum. The only
well-established genetic risk factor for late onset AD
(LOAD) is the E4 allele of apolipoprotein E although many
lifestyle risk factors have been reported including low ed-
ucation, midlife high blood pressure and cholesterol levels,
obesity, and diabetes (Rogaeva, 2002). It has been estimated
that the four established AD genes account for less than
30% of the genetic variance in EOAD and LOAD, suggest-
ing that numerous additional AD genes may exist (Daw et
al., 2000). The pursuit of these additional genes has been
unproductive until recently. In the last 2 years, however,
high throughput technologies able to genotype up to one
million single nucleotide polymorphisms (SNPs) have re-
vealed some of the genetic players in different complex
disorders. In this review, we will consolidate the current
knowledge on the role of APP, PSENs, and APOE in AD,
we will systematically review the most promising new loci
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discuss the recent advances in AD genome wide analysis in
the context of the known epidemiology of the disorder.
1.1. Early onset Alzheimer’s disease causative genes
(APP, PSEN1, and PSEN2)
The amyloid precursor protein gene (APP, OMIM
104,760, chromosome 21q21) encodes a ubiquitously ex-
pressed, integral Type I membrane glycoprotein that exists
as different alternatively spliced isoforms, with three pre-
dominant ones: APP751, APP770, and APP695, the latter
being the main isoform found in the brain (Yoshikai et al.,
1990). The proteolytic processing of APP results in the
production of different peptides (including A), after a
eries of secretase cleavages, and occurs through two mu-
ually exclusive pathways: the amyloidogenic pathway (fun-
amentally considered as the pathogenic pathway) and the
on-amyloidogenic or constitutive pathway (Esch et al.,
990; Haass et al., 1992; Shoji et al., 1992). The identifi-
ation of A as a metabolic product of APP and the reports
of AD families harboring APP causative mutations led to
the general concept that A is a key player in the develop-
ent of AD, and that EOAD mutations are influencing the
roperties or ratios of the different A isoforms in the brain
(Hardy, 1997). Dominant mutations in APP are, however, a
rare cause of AD with an estimated frequency of 16% of
familial EOAD patients (Raux et al., 2005). More recently,
two mutations in APP (A673V and E693) have been
reported to cause AD only in the homozygous state in
families with apparently recessive modes of inheritance (Di
Fede et al., 2009; Tomiyama et al., 2008).
In addition to missense variants, copy number mutations
have been identified in autosomal dominant early-onset
families. Five French families (Cabrejo et al., 2006; Rov-
elet-Lecrux et al., 2006) were first reported to harbor small
chromosomal duplications with different break points, but
all including the APP locus. Subsequent screens in Finnish
nd Dutch AD cases revealed additional APP duplications
n EOAD cases with prominent cerebral amyloid angiopa-
hy (CAA) (Remes et al., 2004; Rovelet-Lecrux et al., 2007;
leegers et al., 2006). The phenotypic spectrum of APP
uplications is yet to be fully defined but clearly includes
ixed phenotypes of AD and/or CAA. The estimated fre-
uency of duplications also appears to be variable: in the
elected Rovelet-Lecrux cohort it was 8% (about half the
ontribution of missense APP mutations to early onset,
utosomal dominant AD) (Raux et al., 2005); in the Dutch
ohort less than 2% (Sleegers et al., 2006); in EOAD fa-
ilial and sporadic Swedish and Finnish cases there were
o duplications in APP identified (Blom et al., 2008); and a
requency of 18% was estimated in early onset familial
apanese cases (Kasuga et al., 2009).
The presenilin 1 (PSEN1, OMIM 104,311, chromosome
4q24.3) and presenilin 2 (PSEN2, OMIM 600,759, chro-
osome 1q31-q42) genes have a very similar genetic struc- kure and encode two proteins expressed in a multiplicity of
issues including the brain, with higher levels in the cere-
ellum and the hippocampus and a primarily neuronal ex-
ression (Levy-Lahad et al., 1996; Rogaev et al., 1995).
hese are highly homologous, sharing an overall amino acid
equence identity of 67%. Hydrophobicity plots predicted
hese to be integral membrane proteins (Rogaev et al., 1995)
ost likely adopting a transmembrane structure containing
ine segments with a hydrophilic intracellular loop region
Henricson et al., 2005; Laudon et al., 2005). PSENs are
mportant components of the multimeric gamma-secretase
omplex and are predominantly located in the endoplasmic
eticulum and Golgi compartments, clearly suggesting their
nvolvement in protein processing (Kovacs et al., 1996; De
trooper, 2003). The first disease causing mutations in
SEN1 and PSEN2 were identified in 1995 (Rogaev et al.,
995; Sherrington et al., 1995). Today, 175 pathogenic
utations and seven variants nonpathogenic or with unclear
athogenicity have been identified in PSEN1. PSEN2 har-
ors fewer mutations: 14 pathogenic mutations and nine
ariants nonpathogenic or with unclear pathogenicity
www.molgen.ua.ac.be/ADMutations, accessed in August
009). The PSENs mutation range encompasses mainly
issense mutations scattered all over the proteins, with
ome clustering around transmembrane domains (Guerreiro
t al., 2010; Hardy and Crook, 2001).
.2. Genetic risk for Alzheimer’s disease (APOE)
The apolipoprotein E gene (APOE, OMIM 107,741,
hromosome 19q13.2) encodes a glycoprotein synthesized
ainly in the liver, brain (primarily by neurons and astro-
ytes), and also by other cells such as macrophages and
onocytes (Siest et al., 1995). APOE is involved in the
obilization and redistribution of cholesterol in the periph-
ry and also during neuronal growth and repair (Mahley,
988); in nerve regeneration, immunoregulation and activa-
ion of several lipolytic enzymes (Mahley and Rall, 2000).
he three major APOE isoforms (ApoEII, ApoEIII and
poEIV) differ in two sites of the amino acid sequence
residues 112 and 158) and are encoded by a single genetic
ocus. The frequencies of the 2, 3, and 4 alleles were
estimated at 0.11, 0.72, and 0.17, respectively, but vary
widely among populations (Zannis et al., 1981). The 4
allele, (the ancestral allele), is more frequent in populations
such as Pygmies (0.407) and Khoi San (0.370). The 2
allele frequency oscillates with no apparent trend and, for
example, is absent in some Native Americans populations
(Corbo and Scacchi, 1999).
Many studies have demonstrated an association between
the 4 allele and familial and sporadic forms of LOAD. This
allele represents an increased risk seen across different
ethnic groups of 3-fold for heterozygous carriers and up to
15-fold for individuals who are 4 homozygotes, when
compared with 3 homozygotes (Ashford, 2004). APOE is
nown to act in a dose dependent manner in AD: the effect
439R.J. Guerreiro et al. / Neurobiology of Aging 33 (2012) 437–456of the 4 allele in the risk for AD increases from 20% to
90% and the mean age of onset decreases from 84 to 68
years with the increase in the number of 4 alleles (Corder
et al., 1993). The 2 allele has been shown to have an
impact on longevity and may confer protection against AD
(Corder et al., 1994). Distinct binding properties of the
different APOE isoforms to the A peptide (Strittmatter et
al., 1993) and tau protein (Strittmatter et al., 1994) have
been suggested to underlie the disparities associated with
each genotype. In particular, the ApoEIV isoform binds to
the A peptide more rapidly than the ApoEIII isoform,
forming novel monofibrils that precipitate into dense struc-
tures (Sanan et al., 1994). The fact that ApoEIV does not
bind to tau protein in vitro, unlike ApoEII and ApoEIII, has
suggested to some that this interaction between ApoEIII and
tau serves as a protection against tau phosphorylation and
consequent neurofibrillary tangle formation (Strittmatter et
al., 1994; Weisgraber, 1994).
The 4 allele appears to be a risk factor and not an
invariant cause of AD, indicating that other environmental
or genetic factors may need to be concurrently acting with
this allele to cause AD (Hyman et al., 1996). For example,
physical activity has been shown to be protective for de-
mentia in non-APOEe4 carriers (Podewils et al., 2005).
Additionally, while most of the risk at the APOE locus is
likely to be encoded at the protein coding polymorphism, it
is likely that other genetic variability at this locus, probably
altering APOE expression, also contributes to the risk of
developing AD (Bekris et al., 2009; Chartier-Harlin et al.,
1994; Lambert et al., 1997; Lambert et al., 2002). Genetic
variability in APOE expression may contribute more to
disease risk, rather than independent effects of the adjacent
gene TOMM40.
During the past two decades there have been many stud-
ies searching for genetic risk factors: hundreds of positive
and negative results have been produced, but none apart
from APOE have produced clear and reproducible associa-
tions.
2. Different types of studies in AD genetics
Methodologically, two main genetic strategies have gov-
erned the field: genetic linkage analysis and case-control
association studies. For linkage analysis, researchers have
used informative families where a clear heritability of the
disease is present and no mutations have been found. In
association studies, researchers compare the frequencies of
a predetermined allele between a group of AD cases and a
group of healthy individuals. Several considerations are
relevant for both strategies, of which we will mention the
main ones. A full discussion of all methodological issues
involved in these types of studies goes beyond the scope of
this review. Here we will briefly describe the known genes
and risk factors associated with AD, with a focus on genome
wide association studies (GWAS) as a methodology forexploring genetic susceptibility and identifying risk factors
and mechanisms for disease. We will also address the pre-
viously overlooked role of homozygosity and recessive
cases in the major complexity of AD genetics.
2.1. Linkage studies
Genetic linkage studies aim to identify chromosomal
regions associated with disease by measuring the correlated
segregation of particular markers with a determined pheno-
type within a family (Teare and Barrett, 2005). This type of
study usually involves three sequential steps: 1) the identi-
fication of the disease causative locus; 2) sequencing the
region found in the previous step in a cohort of cases and
controls to define and characterize the mutation(s) found; 3)
uncovering the molecular and biological functions of the
genes found (Altshuler et al., 2008). Several factors are
known to complicate this approach in AD: i) difficulties in
getting large, complete and informative multigeneration
families; ii) the potential inclusion of phenocopies (individ-
uals with a sporadic indistinguishable form of disease); and
iii) genetic heterogeneity, since observing that the pattern of
disease in families is consistent with a major gene compo-
nent does not necessarily imply that only one gene or factor
is involved. Additionally, linkage mapping suffers from
limitations, such as the low resolution of the results. Usually
these studies do not identify one gene or one mutation
associated with a disease, but rather a chromosomal region
(many times, a very large region) is identified. In addition,
the strongest linkage signals tend to come from recessive
and highly penetrant, thus very rare, disorders (Teare and
Barrett, 2005).
Nonetheless, linkage mapping has been a very important
methodology in the study of AD genetics. The four genes
undoubtedly associated with AD were identified primarily
by linkage analysis. In addition to these genes, several other
genomic regions have been implicated using this method-
ology (Table 1). These loci contain many genes that have
been considered candidates and consequently have been
studied to identify the genetic variation responsible for the
development of AD. Until now, no specific genes impli-
cated in AD have been identified in these regions. Most
recently, a study by Butler and colleagues used a meta-
analysis method to analyze the pooled linkage results from
five independent genome scans. These included the results
of 2,206 affected individuals and 785 families of Caucasian
and Caribbean Hispanic descent. This study was able to
identify genome-wide suggestive evidence for linkage on
chromosomes 1p13.3-q31.1, 7pter-p21.1 and 8p22-p21.1,
together with other seven loci presenting nominally signif-
icant evidence for linkage (Butler et al., 2009). Interest-
ingly, the most significant locus identified in this study
(8p22-p21.1) includes the CLU gene, (the top hit from the
largest GWAS performed in AD, as discussed below in this
review) and previously reported loci by different studies (as
9p, 9q, 10q, and 12p) were not identified by Butler and
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identify risk factors in LOAD, probably due to the low odds
ratios associated with the unidentified variants.
2.2. Gene association studies
The quest for genetic risk factors in clinical genetics has
mainly focused on the study of candidate genes (usually
focusing only on variants altering the coding sequence of a
gene). These types of studies rely on a rather simple prin-
ciple: to test if a determined allelic or genotypic variant
occurs more or less often in a group of people with a
particular disease when compared with a similar group of
healthy individuals.
Table 1
Ten most interesting AD linkage regions
Chr Region Number
of studies
Studies
1 1p13.3-q23.3 2 (Liu et al., 2007); (Butler et al., 2009)
1q23.3-q31.1 3 (Liu et al., 2007); (Butler et al., 2009);
et al., 2003)
5 5p13-p15 6 (Pericak-Vance et al., 2000); (Curtis et
(Olson et al., 2002); (Myers et al., 2002
(Blacker et al., 2003); (Lee et al., 2006
8 8p22-p21.1 2 (Butler et al., 2009); (Lee et al., 2008)
9 9p21 5 (Pericak-Vance et al., 2000); (Curtis et
(Myers et al., 2002); (Scott et al., 2003
(Hamshere et al., 2007)
9q22-q34 8 (Pericak-Vance et al., 2000); (Curtis et
(Olson et al., 2002); (Myers et al., 2002
(Blacker et al., 2003); (Holmans et al.,
(Lee et al., 2006); (Hamshere et al., 20
0 10q21-q22 7 (Curtis et al., 2001); (Olson et al., 2002
et al., 2002); (Blacker et al., 2003); (Ho
al., 2005); (Liu et al., 2007); (Hamsher
2007)
2 12p11-p13 4 (Pericak-Vance et al., 1997); (Curtis et
(Myers et al., 2002); (Holmans et al., 2
9 19q12-q13.33 9 (Pericak-Vance et al., 2000); (Curtis et
(Olson et al., 2002); (Myers et al., 2002
al., 2002); (Blacker et al., 2003); (Holm
2005); (Hamshere et al., 2007); (Sillen
2008); (Butler et al., 2009)
1 21q21-q22 4 (Olson et al., 2002); (Myers et al., 2002
(Blacker et al., 2003); (Holmans et al.,
ote that: results by (Kehoe et al., 1999) and (Lee et al., 2004) were not con
creen (Myers et al., 2002 and Lee et al., 2006, respectively). The results b
tudied by Kehoe et al. (1999); Myers et al. (2002); Blacker et al. (2003
eanalyses of existing data either by incorporating other variables (such
Avramopoulos et al., 2005), (Hollingworth et al., 2007)), or parent of ori
Hahs et al., 2006) on Amish families were not considered due to the inc
hese regions were selected either from the top three regions resulting f
verlapping between four or more whole-genome studies assessing linkage
egions observed in full genome screens (www.alzforum.org/res/com/gen/a
btained from crosschecking with the AlzGene database (www.alzgene.orThe success of this approach relies in an in-depth under-standing of the disease and disease pathways, in such a way
that the researcher will be able to select, not only the right
gene, but also the right variant(s) to be studied. Addition-
ally, the two studied groups need to be homogeneous, well
characterized and large enough to allow a statistically pow-
erful analysis (Hattersley and McCarthy, 2005).
Most gene association studies in AD have studied a few
variants in one or two genes. The large number of genes and
even more variants, clearly reduce the chances of true pos-
itive findings. Nonetheless, several hundreds of positive
associations have been reported. Most of these are certainly
false positives resulting mainly from population substruc-
ture (i.e. existence of subpopulations in which there was
LOD scores Relevant genes
5.2 GSTM4; GSTM1; GSTM3; CSF1; NGF; HMGCS2,
PRKAB2; APH1A; CTSS; THEM5; FAM63A;
CHRNB2; LMNA; PMVK; FDPS; APOA1BP;
GBA; NTRK1; CRP; NCSTN
r 2.1–4.0 F11R; USF1; FCER1G; RGS4; APOA2; RXRG,
POU2F1; PRDX6; SOAT1; PTGS2
1); 1.4–2.8 SLC6A3; PRKAA1
 2.0 NAT1; NAT2; LPL; ADRA1A; CHRNA2; CLU
1);  1.0–4.6 IFT74
1); 1.6–4.2 FBP1; GOLM1; ABCA1; DFNB31; TLR4;
NDUFA8; PSMB7; HSPA5; POMT1; DBH;
RXRA; TRAF2; ABCA2
rs
et
1.8–4.15 ZWINT; UBE2D1; TFAM; BICC1; ANK3; CDC2;
EGR2; CTNNA3; LRRTM3; DNAJC12; SIRT1;
SRGN; SUPV3L1; TSPAN15; VPS26A; HK1;
TACR2; NEUROG3; SAR1A; SGPL1; PSAP;
CHST3; PPP3CB; SEC24C; NDST2; CAMK2G;
PLAU; VCL; AP3M1; MYST4; KCNMA1
1); 1.4–3.9 TNFRSF1A; CNAP1; GAPDH; GNB3; C1R;
APOBEC1; MMP-3; A2M; PZP; A2MP; OLR1;
LRP6; GRIN2B; GYS2; ABCC9; PKP2P1
1);
t
al.,
1.6–7.7 LRP3; USF2; GAPDHS; PSENEN; AKT2; TGFB1;
Lipe; XRCC1; Bcl-3; APOE; PVRL2; TOMM40;
APOC1; APOC2; ERCC2; CARD8; GYS1; LHB;
CD33; NR1H2
1.6–4.5 PRSS7; NCAM2; APP; C21orf63; C21orf55;
RUNX1; C21orf55; DYRK1A; KCNJ6; BACE2
as they were significantly extended in the same groups’ follow-up genome
shere et al. (2007) consist of an amalgamated of three datasets previously
olmans et al. (2005). Other studies have been published that performed
idence for AD with and without psychosis (e.g. (Bacanu et al., 2002),
cts, e.g. (Bassett et al., 2002). Results by (Ashley-Koch et al., 2005) and
f MCI cases.
e recent meta-analysis performed by Butler and colleagues, or from the
D risk, based on the AlzGene database of concordant linkage/association
/linkage.asp). The relevant genes for each of the represented regions were
tram et al., 2007)).(Blacke
al., 200
);
)
al., 200
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2005);
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ancestry of cases and controls are not matched) (Tian et al.,
2008), poor statistical analysis and publication bias toward
positive results (Choudhry et al., 2006; Ioannidis et al.,
2001). Positive associations have been broadly published,
while negative results (unless convincingly refuting previ-
ous results) would not be reported. When reported, most of
these studies pointed to small sample sizes, or specific
genetic population backgrounds as main reasons for the
negative results. Other issues, particularly in large epidemi-
ologic studies, include case definition or the ability to ac-
curately identify AD versus vascular or other forms of
dementia; age of dementia onset estimation; and phenotypic
variations in the disease whether cognitive, vascular, psy-
chiatric or metabolic.
To address these very large numbers of conflicting re-
ports, a database (the AlzGene database) was created which
systematically collects, summarizes and meta-analyzes the
results for all the genetic variants studied in association with
AD (Bertram et al., 2007). As of 16th November 2009 the
top 10 results in this database included: APOE (E2/3/4),
CLU, PICALM, TNK1, ACE, TFAM, CST3, IL1B, CR1 and
CG2039140 (Bertram and Tanzi, 2008). The fifth top hit,
CE, has repeatedly been reported as associated with AD
Webster et al., 2009), atherosclerosis (Sayed-Tabatabaei et
l., 2003) and hypertension (Staessen et al., 1997). The role
f vascular risk factors in AD is further discussed below.
.3. Genome wide association studies
The development of platforms able to genotype millions
f SNPs and of powerful analytical frameworks, able to
istinguish true associations; together with the completion
f the International Human HapMap project (International
uman HapMap Consortium, 2005), have provided unprec-
dented tools to the study of the so-called “Common Dis-
ase-Common Variant” (CD–CV) hypothesis. This theory
roposes that common polymorphisms (usually defined as
aving a minor allele frequency of over 5%) may contribute
o the overall susceptibility to common diseases (Cargill et
l., 1999; Chakravarti, 1999; Lander, 1996). This type of
nalysis addresses one of the major pitfalls of gene associ-
tion studies: the coverage of the study. Instead of studying
ne or two genetic variants, we are now able to test most
ommon variability in the genome for association with
isease, by means of testing tagging SNPs, i.e. polymor-
hisms in linkage disequilibrium (LD) with each other. This
eans that if one knows the genotype in one locus, one can
redict with a high accuracy (dependent on the strength of
he LD and the allele frequencies) the genotype occurring at
inked loci. However, these platforms require the analyses
f large numbers of samples and some regions of the ge-
ome are still not well covered. Thus, the success of GWAS
epends on sample size, frequency of risk alleles and indi-
idual effect sizes. The smaller the attributable risk associ-
ted with any given common variant, the greater the number lf samples needed to identify that variant. The risk allele
requency relates to the effect size: a risk variant that has a
igh odds ratio but is rare in the population is much more
ifficult to identify with GWAS than a common variant
inked to moderate or mild risk within the population. Ad-
itionally, population stratification (when cases and non-
ases are not genetically similar); population admixture
when several distinct, unrecognized subpopulations com-
rise the same group of individuals studied) and unreported
elatedness in the population may also be problems if the
tudy is not correctly designed (Simon-Sanchez and Single-
on, 2008).
The competing hypothesis to explain the genetic basis of
omplex diseases is the “Common Disease-Rare Variant”
CD–RV) theory, which suggests that multiple rare variants
nderlie susceptibility to such diseases (Fearnhead et al.,
005). Although the CD–CV versus CD–RV is a false
ichotomy, it has major implications for the future of the
esearch in this field, since different techniques are used to
nd common versus rare alleles. By definition, rare variants
ave low frequencies (MAF  0.1% to 2–3%) and individ-
ally small contributions to the overall inherited suscepti-
ility of a disease. In this way, rare variants will not be
etectable by GWAS. Instead, the choice of candidate genes
nd appropriate case groups has been essential to uncover
his type of variants (Bodmer and Bonilla, 2008). The new
equencing technologies will facilitate this approach by
llowing the assessment of all the genes in the genome.
onetheless, the extensive DNA resequencing of the whole
enome in large numbers of individuals, and the assessment
f the functional consequences of the variants found, poses
ifficult bioinformatic and data management challenges.
There is no doubt that GWAS have uncovered previously
nknown polymorphic variants and genes with significant
ffects on AD risk. However, considering the studies so far
arried out in AD (see next section for details), the associ-
tions still to be found will have ORs lower than 1.2. This
as raised the question as to whether it is worthwhile to
ursue even larger GWAS to identify variants with small
ffects disease risk. Certainly, in the future, sequencing and
ssociation strategies will be employed together to fully
issect the genetic architecture of the risk of AD and other
omplex disorders (Bodmer and Bonilla, 2008).
Since APOE has been the only risk factor consistently
ssociated with LOAD and some reports have estimated a
eritability of AD between 60% and 80% (Gatz et al., 2006;
edersen et al., 2001) it is believed that genetic variability
lays a critical role in LOAD and that several risk factors
re still to be uncovered. Daw and colleagues had estimated
he existence of four to seven additional genes contributing
o this genetic variability (Daw et al., 2000).
Several GWAS in AD have now been published (Table
). The first study of this type was performed by Grupe et
l., in which the approach used was to first generate a short
ist of candidate SNPs by analyzing 17,000 SNPs in DNA
Table 2
Main features and results of genome wide association studies performed in AD
Study Platform No.
SNPs
Population Genotype
data publicly
available
No. subjects Replication stage(s) Significant results
Cases Ctrls
Grupe et al., 2007
(Grupe et al.,
2007)
Celera (cSNPs) 17343 UK and USA no 380 396 4 replication tiers (UK2, 309
cases349 controls; UK3, 503
cases643 controls; WU, 376
cases344 controls; SD, 240
cases330 controls)
total number of samples (four
tiers)  1428 cases  1666
controls
rs157581 (TOMM40, chr 19q13.32)
rs405509 (APOE, chr 19q13.32)
rs3745833 (GALP, chr 19q13.42)
rs1554948 (TNK1, chr 17p13.1)
rs1132899 (APOC2, chr 19q13.32)
rs11622883 (14q32.13)
rs8192708 (PCK1, chr 20q13.31)
rs505058 (LMNA, chr 1q22)
rs3800324 (PGBD1, chr 6p22.1)
rs6907175 (LOC651924, chr 6q24.1)
rs1859849 (7p15.2)
rs41310885 (hCV22274641,
FAM63A, chr 1q21.2)
rs2074877 (MYH13, chr 17p13.1)
rs41271951 (hCV15746640, CTSS,
chr 1q21.2)
rs444013 (UBD, chr 6p22.1)
rs9608099 (BCR, chr 22q11.23)
rs2882676 (ACAN, chr 15q26.1)
rs13022344 (TRAK2, chr 2q33.1)
rs11016976 (EBF3, chr 10q26.3)
Coon et al., 2007
(Coon et al.,
2007)
Affymetrix
(500K)
502627 USA, Netherlands;
overlaps with
Reiman et al. (2007)
no 664 422 no rs4420638 (APOC1, chr 19q13.32)
Reiman et al.,
2007 (Reiman
et al., 2007)
Affymetrix
(500K)
312316 USA, Netherlands;
overlaps with
Coon et al. (2007)
yes 446 290 neuropathological replication cohort
(197 cases  114 controls); clinical
replication cohort (218 cases  146
controls)
total number of samples (two
cohorts)  415 cases  260
controls
rs901104; rs1385600; rs1007837;
rs2510038; rs4945261; rs7101429;
rs10793294; rs4291702; rs7115850;
rs2373115
(GAB2, chr 11q14.1)
Liu et al., 2007
(Liu et al.,
2007)
Affymetrix
(500K)
262000 Netherlands no 103 LOAD patients and 170
first-degree relatives from a
pedigree with 4645
members
4173 SNPs in 197 unrelated
subjects from the GRIP population
Chr 1q25 (RGSL2, RALGPS2,
C1orf49);
Chr 3q22-24 (NMNAT3, CLSTN2);
Chr 10q22-24 (HTR7, MPHOSPH1,
CYP2C);
Chr 11q25 (OPCML, HNT)
Li et al., 2008 (Li
et al., 2008)
Affymetrix
(500K)
469438 Canada and UK yes 753 736 120 SNPs in 418 cases  249
controls
rs10868366; rs7019241 (GOLM1,
chr 9q21.33)
rs4420638 (APOC1, chr 19q13.32)
also significant in Coon et al. (2007);
rs10519262 (chr 15q21.2); rs9886784
(chr 9p24.3)
(continued on next page)
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Table 2
(continued)
Study Platform No.
SNPs
Population Genotype
data publicly
available
No. subjects Replication stage(s) Significant results
Cases Ctrls
Abraham et al.,
2008 (Abraham
et al., 2008)
Illumina
HumanHap300 
Illumina
Sentrix
HumanHap240S
561494 UK no 1082 LOAD pooled 1239 controls
pooled
114 SNPs were individually
genotyped in the cases and controls
used in the pools and 1400 controls
were added
ApoE; rs727153 (13 kb from the
start of transcription of LRAT, chr
4q32.1), also showed increased
significance (10-fold) when
additional controls were combined
Bertram et al.,
2008 (Bertram
et al., 2008)
Affymetrix
500K
484522 self-reported
European descent
from NIMH
Genetics Initiative
Study sample
no AD 1376 from 410 families 4 SNPs in 3 independent AD
family samples:
NIA- 1040 samples from 329
families; NCRAD- 1108 samples
from 331 families; CAG- 483
samples from 215 sibships (total:
2689 samples 1816 affected and
845 unaffected)
Rs 4420638 (located 340 bp 3= of
APC1 and probably reflects the
effects of apoE E4 allele);
rs 11159647 (in predicted gene
NT_026437.1360, chr14q31.2), also
significant in replication samples and
in TGEN’s data;
rs179943 (in ATXN1, chr 6p22.3),
trend for significance in replication
samples;
rs3826656 (in predicted gene
NT_011109.848, chr 19q13.33), also
significant in replication samples;
rs2049161 (in cDNA BC040718, chr
18p11.31)
Beechmam, 2009
(Beecham et al.,
2009)
Illumina
HumanHap550
532000 USA no 492 load 496 1 SNP in 238 cases  220 controls ApoE;
rs11610206 (downstream of
FAM113B, chr 12q13), also
significant in replication sample
1q42; 4q28; 6q14; 19q13
Carrasquillo et al.,
2009
(Carrasquillo et
al., 2009)
Illumina
HumanHap300
313504 USA no 844 load 1255 25 SNPs in 1547 cases  1209
controls
ApoE;
rs5984894, rs2573905 (in
PCDH11X, chr Xq21.3), also
significant in replication sample
Harold et al.,
2009 (Harold et
al., 2009)
Illumina 610
quad chip
(Illumina
HumanHap550
and
HumanHap300
in some
samples)
529205 Europe
USA
yes 3941 7848 2 significant SNPs in 2023 cases 
2340 controls
ApoE;
rs11136000 (in CLU, chr 8p21-p12),
also significant in replication sample
rs3851179 (5= of PICALM, chr
11q14, also significant in replication
sample)
Lambert et al.,
2009 (Lambert
et al., 2009a)
Illumina
human 610-
quad BeadChip
537029 Europe no 2032 5328 significant SNPs in 3978 probable
AD cases  3297 controls from
Belgium, Finland, Italy and Spain
rs11136000, rs2279590, rs9331888
(in CLU, chr 8p21-p12), also
significant in replication sample
rs6656401 (in CR1, chr 1q32), also
significant in replication sample
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only covers a small proportion of the genome, probably
around 5%, and is not strictly “genome-wide”. In this study,
markers meeting a previously defined significance criteria
were then typed in DNA pools from a second set of samples
and, again the SNPs satisfying the criteria were then indi-
vidually genotyped in four sets of cases and controls and
finally in a fifth sample. In total, nearly 4,000 samples
(AD 2000 cases, 2000 controls) from the USA and the
UK were studied. Three SNPs on chromosome 19 in LD to
APOE represented the most significant associations, of
which two (rs157581 in TOMM40 and rs405509 in APOE)
achieved genome-wide significance. SNPs in other genes
reached nominal significance but did not achieve genome
wide significance (Grupe et al., 2007).
The first studies covering most of the genome were
published by Coon et al. (Coon et al., 2007) and Reiman et
al. (Reiman et al., 2007) (1,000 cases and controls). In
these studies on largely the same dataset, only a single SNP
in LD with APOE (rs4420638) reached genome wide sig-
nificance although SNPs in GAB2 (rs2373115) reached sig-
nificance when the AD cases were stratified by APOE ge-
notype (Reiman et al., 2007). An analysis of the top hits
from AlzGene in the same dataset found that only SNPs in
ACE reached nominal significance (Webster et al., 2009).
Liu et al. reported on a genome screen of 402 microsat-
ellite markers in 103 LOAD patients and 170 first-degree
relatives from a pedigree with 4,645 members from the
Netherlands. Multipoint analysis revealed four significant
(1q21, 1q25, 10q22-24 and 3q22-24) and one suggestive
(11q24-25) linkage peaks. Several of these regions coincide
with previously reported loci (Table 1) with the strongest
linkage association found for chromosome 1q21. Following
these results, the authors tested for association between
cognitive function and 4,173 SNPs in the linked regions in
an independent sample consisting of 197 individuals from
the same Genetic Research in Isolated Populations program.
After adjusting for multiple testing, significant associations
were identified in four (1q25, 3q22-24, 10q22-24 and
11q25) of the previous five regions (Liu et al., 2007).
Abraham and colleagues performed a genome-wide as-
sociation study in pooled DNA samples of 2000 LOAD
cases and  1,000 controls. They identified a set of 109
SNPs with a significant association with AD and genotyped
them individually. In addition to APOE, one SNP
(rs727153), located approximately 13 kb apart from the start
of LRAT transcription site, was suggested as associated with
isease (Abraham et al., 2008).
Li et al. (2008) studied a hypothesis-generating cohort
rom Canada and identified rs4420638 within APOC1 to be
trongly associated with AD, due to LD with APOE (Coon
t al., 2007) but nothing else reached genome wide signif-
cance (Li et al., 2008).
Bertram et al. (2008) used samples from 410 AD families
o identify five SNPs significantly or marginally associatedith a multivariate phenotype combining age at onset of the
isease and affection status. The marker presenting the most
ignificant association was again rs4420638 (located 340 bp
= of APOC1) and almost certainly reflecting the effects of
POE 4 allele. Once more, no other SNP reached genome
ide significance (Bertram et al., 2008).
Beecham and colleagues analyzed 500 LOAD cases
nd 500 cognitive controls followed by a further  200
ases and  200 controls used as a validation dataset for
NPs that reached nominal, but not genome-wide signifi-
ance. They too, were able to confirm association with the
POE locus and they suggest an association with the 12q13
ocus, which they replicated in the validation dataset. The
ssociated SNP (rs11610206) is close to the hypothetical
ene FAM113B. Additionally, there are some nearby can-
idate genes, such as VDR and AMIGO2. To validate asso-
iated SNPs with p values  0.0001 and nominally associ-
ted candidate genes, they imputed SNPs from a previously
ublished GWAS (Reiman et al., 2007). Four additional
ighly associated signals were replicated using the imputed
ataset: 1q42 (within DISC1); 4q28 (200 kb proximal to
CDH18); 6q14 (nearest gene is BCKDHB); and 19q13
within ZNF224) (Beecham et al., 2009).
By analyzing 1,000 LOAD cases and 1,000 controls
nd evaluating the 25 SNPs with the most significant allelic
ssociation in four additional series, Carrasquillo and col-
eagues suggested an association with the X chromosome SNP
s5984894 in PCDH11X (Xq21.3) (Carrasquillo et al., 2009)
ut again, this association did not reach genome wide signifi-
ance.
Feulner et al. generated genome-wide data in a German
ohort of AD 500 patients and 500 controls. The results
btained were analyzed only for the genes included in the
op results list on the AlzGene database. Additionally to
POE, nominally significant associations were found for
ix of the 10 studied genes (CH25H, PGBD1, LMNA,
CK1, MAPT and SORL1) (Feulner et al., 2009) but none of
hese putative signals reached genome wide significance.
All the above studies, which each used  2,000 Alzhei-
er cases in their analysis, were able to pick up the signal
t the APOE locus, but despite tantalizing results, none were
ble to identify other loci at a level which passes the thresh-
ld for genome wide significance, and no two of them
dentified the same locus. The data from the Reiman et al.
nd by Li et al. studies, were made publicly available
www.tgen.org/research/neuro_gab2.cfm and www.GSK.
om, respectively) to enable their additive use in other
tudies. Overall, these data pointed to the need for larger
tudies to identify risk loci with smaller effect sizes. Two
uch studies have now been reported.
One of these studies reported the analysis of 4,000
ases and 8,000 controls in Stage 1 and 2000 cases and
2000 controls in Stage 2. Two SNPs significantly associ-
ated with AD, outside the APOE locus, were identified:
rs11136000 located in an intron of CLU on chromosome 8
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mosome 11. Although the risks associated with CLU and
PICALM genes are relatively small (APOE odds ratio 4;
CLU/PICALM 1.1) these associations reached genome
wide significance (Harold et al., 2009). The other large AD
GWAS reported on 2000 cases and 5,000 controls in the
first stage, and 3,000 cases and 3,000 controls in the
replication stage. An association between AD and ApoE,
CLU and CR1 locus on chromosome 1q32 (OR  1.2) was
ound (Lambert et al., 2009b).
These aforementioned genes (CLU, CR1 and PICALM)
ill clearly be the subject of intense research. Here we will
iscuss the main features of each of these genes, as well as
he potential pathobiological pathways in which they may
e involved in the context of AD.
Clusterin or apolipoprotein J is, like APOE, a lipoprotein
xpressed in most mammalian tissues with higher levels
resent in brain, ovary, testis and liver (de Silva et al.,
990). CLU interacts with different molecules, including
ipids, amyloid proteins, components of the complement
embrane attack complex (MAC) and immunoglobulins
Jones and Jomary, 2002). Accordingly, it has been pro-
osed to be involved in a number of physiological processes
uch as ongoing synapse turnover (Danik et al., 1993),
poptosis (Jenne and Tschopp, 1992; Wong et al., 1993),
ytoprotection at fluid-tissue boundaries, membrane recy-
ling during development and in response to injury and
egulation of complement-mediated MAC (Jones and Jom-
ry, 2002; Oda et al., 1994). Clusterin has also been pro-
osed to be a form of secreted heat-shock protein or chap-
rone molecule (Michel et al., 1997; Wilson and
asterbrook-Smith, 2000).
Several lines of evidence suggest that CLU has a central
either protective or pathogenic) role in the pathway leading
o Alzheimer’s disease. First, CLU mRNA has been re-
orted to be elevated in AD affected brain areas such as
ippocampus, either when brains from AD patients were
ompared with one Huntington patient (Duguid et al.,
989), or to controls (May et al., 1990). Likewise, Oda et al.
eported a statistically significant difference in the clusterin
rotein content of extracts from cortex and hippocampus
hen comparing 10 non-AD individuals and 25 AD patients
Oda et al., 1994). Second, clusterin is one of the compo-
ents of amyloid plaques (Kida et al., 1995; McGeer et al.,
992; McGeer et al., 1994; Takamaru, 1994). Third, is able
o bind soluble A through a specific, reversible and high-
affinity interaction in cerebrospinal fluid (Ghiso et al., 1993;
Golabek et al., 1995) to form complexes able to cross the
blood–brain barrier by a high affinity receptor mediated
process involving transcytosis (Zlokovic, 1996). Fourth,
reduced levels of APOE and increased levels of CLU have
been correlated with the number of E4 alleles, suggesting a
compensatory induction of CLU in the brain of AD indi-
viduals with the 4 allele of APOE presenting low brain
levels of APOE (Bertrand et al., 1995). Moreover, CLU wasshown to prevent aggregation and polymerization of syn-
thetic A and to enhance the oxidative stress caused by A
in vitro (Matsubara et al., 1996; Oda et al., 1995), and to
facilitate A uptake in cell culture experiments (Hammad et
al., 1997). Clusterin appears to regulate the toxicity and
conversion of A into soluble forms (Boggs et al., 1996;
deMattos et al., 2002; Matsubara et al., 1996; Oda et al.,
1995). Together with APOE, suppresses A deposition (de-
Mattos et al., 2004) and may modify A clearance at the
lood brain barrier (Bell et al., 2007). More recently we
ave established that common coding variability in CLU
oes not explain the association, and that there is no large
ffect of common genetic variability on expression in brain
issue. Our negative results lead us to hypothesize that the
ost likely mechanism underpinning the association is ei-
her small effects of genetic variability on resting gene
xpression, or effects on damage induced expression of the
rotein (Guerreiro et al., 2010).
PICALM, encodes the phosphatidylinositol-binding
lathrin assembly protein, also known as CALM: clathrin
ssembly lymphoid-myeloid leukemia gene. It is ubiqui-
ously expressed with particularly high levels in neurons.
his gene has been associated with leukemia, thus its rela-
ion to AD may appear not as direct as the one observed for
LU (Fig. 1). Nonetheless, its involvement in clathrin-
ediated endocytosis (essential to the intracellular traffick-
ng of proteins and lipids) (Kim and Kim, 2001) and in the
usion of synaptic vesicles to the presynaptic membrane by
irecting the trafficking of VAMP2 (Harel et al., 2008) have
ead Harold et al. to propose two interesting hypotheses for
he role of Picalm in AD. In this way, genetic variability in
ICALM may result on synapse perturbations, possibly
hrough synaptic vesicle cycling, or on alterations of APP
rocessing through endocytic pathways, culminating in
hanges in A levels (Harold et al., 2009). Interestingly,
Harold et al. also showed a suggestive evidence for associ-
ation with AD for the gene BIN1 (AMPH2, amphiphysin
isoform 2, located on chromosome 2q14). This gene also
encodes a protein known to be involved in synaptic vesicle
endocytosis (Takei K., et al 1999) and is one of Picalm
interactors’ in Figure 1, reinforcing a role for these proteins
in a new AD pathobiological pathway.
CR1, the complement component (3b/4b) receptor 1
(Knops blood group) is a member of the receptors of com-
plement activation family. The gene encodes a monomeric
single-pass Type I membrane glycoprotein found on erythro-
cytes, leukocytes, glomerular podocytes, and splenic follicular
dendritic cells that mediates cellular binding to particles and
immune complexes that have activated complement (Ahearn
and Fearon, 1989).
Three complement pathways are known: the classical,
alternative and lectin-mediated cascades, which have differ-
ent activation triggers, but all terminate with the production
of the membrane attack complex. High enough concentra-
tions of MAC result in cell lysis. This may lead to tissue
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(that occurs through the action of several different endoge-
nous complement inhibitor proteins), is deficient (Sjoberg et
al., 2009). Typically, the complement classical pathway is
the one associated with AD (Akiyama et al., 2000), mainly
due to three facts: 1) C1q, the first protein in this pathway,
efficiently binds to aggregated A, activating the pathway
and further enhancing A aggregation and fibril formation
Rogers et al., 1992; Webster et al., 1995); 2) early com-
lement activation proteins (C1q, C4 and C3) and the MAC
ave been found to colocalize with senile plaques, NFTs
nd dystrophic neurites in AD brains (McGeer et al., 1989;
eerhuis et al., 1996; Webster et al., 1997); and 3) increased
RNA levels of complement proteins are present in AD
rains when compared with controls (Walker and McGeer,
992). More recently, activation of the alternative pathway
n AD brains has also been demonstrated: A activates the
alternative pathway in vitro (Bradt et al., 1998); factor B
mRNA is present in AD frontal cortex, and factor D cleaved
split products of factor B (Bb and Ba) are significantly
increased in AD brains (Strohmeyer et al., 2000). After the
discovery that the complement system can be activated in
the brain by several senile plaques and neurofibrillary tangle
related components, in the absence of antibodies, and that
neurons are a source of complement proteins in the brain,
the involvement of the complement system in AD has been
widely accepted (McGeer and McGeer, 2001). However,
whether this involvement has a protective or deleterious
effect has been extensively debated. In fact, it has been
proposed that binding of C1q to misfolded proteins in early
AD, together with C4 binding protein, which decreases the
activation of MAC providing the required physiological
Fig. 1. Predicted interactions for Clu (A), Picalm (B) and CR1 (C).
The software STRING 8.0 (available at http://string.embl.de/newstring-cgi/
used to establish a network of predicted interactions for Clu (A), Picalm (B)
and predicted protein interactions. The interactions include direct (physi
genomic context, high-throughput experiments, (conserved) coexpression
these sources for a large number of organisms, and transfers information be
proteins from 630 organisms.system balance, are favorable and enable clearance of the bmisfolded material. But, when the system is overwhelmed
by amyloid, this protein binds extensively to C1q leading to
the full activation of the complement, ultimately leading to
detrimental inflammation and neurodegeneration (Sjoberg
et al., 2009).
In summary, as in other aging degenerative diseases, the
complement system has an important role in AD, and one
may expect that the activation of the classical or the alter-
native pathways (or both) by A will lead to neurodegen-
ration in individuals with a genetic predisposition (Zipfel,
009). This will possibly result from an unbalance between
he expression of regulator proteins, and one or more cas-
ade proteins (Figure 2). This model is able to explain, at
east partially, the presence of neuropathological changes in
he brains of nondemented individuals (Hof et al., 1996)
ince the genetic variability in the complement genes may
e responsible for different complement reactions to the
resence of NFT and senile plaques. Interestingly, as men-
ioned above, one function attributed to clusterin is in the
egulation of complement-mediated membrane attack com-
lex. Together with vitronectin, clusterin binds to the nas-
ent amphiphilic C5b-9 complex, rendering it water-soluble
nd lytically inactive, raising the possibility that the genetic
isk conferred by clusterin for the development of AD, may
rise from its regulation role in the complement system.
. Vascular risk factors and Alzheimer’s disease
These genetic findings point to the role of tissue and
ascular damage in AD pathogenesis and thus to vascular
isk factors in its etiology. It is noteworthy that many of
he genes now implicated potentially have a direct role at the
put_page.pl? UserId75H-lKjgP5Xi & sessionId9vx3bNEK6tmB) was
1 (C) proteins. Accessed in August 2009. STRING is a database of known
d indirect (functional) associations; they are derived from four sources:
vious knowledge. STRING quantitatively integrates interaction data from
hese organisms where applicable. The database currently covers 2,483,276show_in
and CR
cal) an
and pre
tween tlood brain interface: this includes APOE, ACE and the
(
a
(
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As such, these findings are consistent with the epidemio-
logic literature, which has consistently reported an associ-
ation between vascular risk factors and AD. The evidence
base for the prevention of AD and related brain pathologies
is strongest for control of vascular risk factors (Gustafson D
and Skoog I, 2009). Overweight and obesity is a cornerstone
of vascular risk, which predisposes to hypertension, hyper-
cholesterolemia, diabetes, and cardiovascular disease. In-
deed, the low-risk ratios observed in genetic studies at-
tempting to identify new susceptibility genes for AD may be
due to lack of information on presence and/or severity of
this vascular involvement, as well as to the differential
expression and clustering of vascular and metabolic traits.
AD brain pathologies exist against a background continuum
of vascular pathologies, which may modulate risk for clin-
ically manifest disease. Vascular factors most directly re-
lated to newly identified susceptibility genes are hyperten-
sion, hypercholesterolemia, and overweight and obesity.
Hypertension is a risk factor for stroke, ischemic white
matter lesions, silent infarcts, general atherosclerosis, myo-
cardial infarction and cardiovascular morbidity and mortal-
ity. This risk increases with increasing blood pressure also
at apparently healthy blood pressure ranges (Kannel, 2000).
Several longitudinal studies have suggested an association
between AD and previous hypertension (Kivipelto et al.,
Fig. 2. Genetic variability and the role of the complement system in AD.
A and probably NFTs are able to activate the classical and alternative c
s) proteins at different stages. The genetic variability in CR1 is now know
re needed to know if the same is true for any other component of these pa
McGeer and McGeer, 2002).2002; Launer et al., 2000; Qiu et al., 2005; Skoog et al.,1996; Stewart et al., 2009). ACE, which is currently (ac-
cessed on 16th November) the fifth top hit on Alzgene
database (Bertram et al., 2007), plays a classical role in
blood pressure regulation as part of the renin-angiotensin
system (Goossens et al., 2003). This system may play a role
in dementia pathogenesis because of its effects on vascular
and metabolic homeostasis, as well as amyloid metabolism.
The gene encoding for ACE is an AD susceptibility gene
whereby effect modification is observed by vascular pheno-
type, particularly with population stratification by vascular
factors such as APOE 4 allele, systolic blood pressure,
body mass index, and obesity indexes (Gustafson et al.,
2008; Katzov et al., 2004). Thus, the renin angiotensin
system may also provide a link between obesity, hyperten-
sion, and vascular syndromes, such as Type 2 diabetes, and
health of the brain (Goossens et al., 2003; Katzov et al.,
2004) because human brain and adipose tissue express the
renin-angiotensin system (Strazzullo et al., 2003).
Cholesterol is important in AD, not only because of its
relationship with cardiovascular disease, but due to its role
in amyloid metabolism (Sparks et al., 1994). APOE and
CLU are two proteins involved in lipid transport in the
peripheral and central nervous systems (Nuutinen et al.,
2009). APOE regulates cholesterol homeostasis in astro-
cytes and microglia, and is related to blood cholesterol
levels (Hoglund and Blennow, 2007). In addition, mutations
ent pathways. These are regulated by several membrane (m) and soluble
associated with the risk of developing AD. Increased numbers of samples
Drawn from the work of Tenner (Tenner, 2001) and McGeer and McGeeromplem
n to be
thways.in the APP gene upregulate A40 and A42 production;
448 R.J. Guerreiro et al. / Neurobiology of Aging 33 (2012) 437–456(Pangalos et al., 2005) and A processing is sensitive to
cholesterol levels and lipid trafficking. Brain cholesterol
levels increase during AD progression (Hoglund and Blen-
now, 2007). The epidemiologic evidence associating high
blood cholesterol levels with AD and other forms of de-
mentia is mixed. High cholesterol levels in midlife may
increase risk for subsequent dementia and AD (Kivipelto et
al., 2002; Notkola et al., 1998; Whitmer et al., 2005), how-
ever, in late-life, low cholesterol levels have been predictive
of subsequent dementia (Mielke et al., 2005; Reitz et al.,
2004) or no association has been observed (Li et al., 2005;
Yoshitake et al., 1995). Nevertheless, even within the
midlife cholesterol literature, results are conflicting, as some
studies have not found high cholesterol to predict later
dementia (Kalmijn et al., 2000; Stewart et al., 2007; Tan et
al., 2003). While there remain a number of questions re-
garding the amyloid hypothesis in relationship to AD, the
potential link to cholesterol metabolism and vascular dam-
age is noteworthy (Hardy, 2009).
Finally, while overweight and obesity appear to increase
risk for dementia independently of other vascular factors,
there is limited evidence related to adipose-specific mech-
anisms of action in AD, particularly in relationship to these
newly identified susceptibility genes. Midlife total or central
obesity measured decades before dementia onset has been
linked to higher risk of dementia in late life (Fitzpatrick et
al., 2009; Gustafson et al., 2009; Kivipelto et al., 2005;
Whitmer et al., 2007; Whitmer et al., 2008). Risky effects of
high BMI as late as in the eighth decade of life have also
been observed (Gustafson et al., 2003; Hayden et al., 2006).
During the prodromal phase of dementia, higher rates of
body weight or BMI decline occur among those developing
dementia (Barrett-Connor et al., 1996; Buchman et al.,
2005; Stewart et al., 2005). Thus, one cannot deny the role
of excess adiposity as enhanced substrate for CR1-related
inflammatory events, nor its potential role in hypertension
and hyperlipidemia. However, also of importance are the
implications of declining metabolic parameters, such as
BMI (Barrett-Connor et al., 1996; Buchman et al., 2005;
Stewart et al., 2005), blood pressure (Stewart et al., 2009)
and cholesterol (Stewart et al., 2007) in AD, for which these
newly identified susceptibility genes may enhance our pre-
cision in identifying subgroups of AD for whom interven-
tions are more advantageous.
4. Possible role of homozygosity and recessive cases
AD, as many other diseases occurring sporadically, re-
curs within families more often than expected by chance
alone. However, in most of the cases, the pattern of familial
recurrence is not compatible with simple Mendelian trans-
mission and this model is typically presumed to reflect a
multifactorial determination with contributions from multi-
ple genes and/or environmental factors (Altshuler et al.,
2008). However, the observed familial recurrence couldalso be attributed to genetic loci with large phenotypic
effects and reduced penetrance (possibly recessive loci). In
this case, one would not necessarily expect to see recurrence
of the disease in multiple generations, nor a high recurrence
rate among siblings, and the disease would be sporadic in
the population. Although without a definite confirmation of
pathogenicity, two rare potentially disease-associated muta-
tions (Q170H and R181G) in ADAM10 (an alpha-secretase
capable of anti-amyloidogenic proteolysis of the amyloid
precursor protein) were recently reported to be associated
with LOAD (Kim et al., 2009). Other mutations in PSEN1
(A79V) (Kauwe et al., 2007) and PSEN2 (N141I) (Levy-
Lahad et al., 1995) have also been reported to be present in
families with non-carriers affected individuals.
Recessive contributions can be inferred when popula-
tions with high degrees of consanguinity present higher
prevalence of the disease than the general population (Mani
et al., 2002). The Wadi Ara population is one example of
this premise: an unusually high prevalence of AD (20% of
those over 65 years and 60% of those over 85 years) in a
population where the 4 allele of APOE is relatively un-
common (Bowirrat et al., 2000; Bowirrat et al., 2001). In
this regard, the study of families with a recessive mode of
inheritance may not only identify the cause of disease in the
respective family, but also be of utility in the identification
of risk factors contributing to the sporadic form of disease.
Populations that have been largely isolated and subjected
to extensive inbreeding during considerable periods in their
recent history represent a powerful resource for the study of
new genetic variants for common diseases. These popula-
tions provide several advantages for genetic research, such
as longer stretches of linkage between neighboring markers,
high levels of genetic and environmental homogeneity and
a simpler genetic architecture for complex traits. Although
these long homozygous tracts of uninterrupted sequences
may represent deletion polymorphisms, loss of heterozygos-
ity or segmental uniparental disomy, recent data suggest
that these, most likely, represent autozygosity (homozygos-
ity by virtue of parental descent from a common ancestor)
(Devilee et al., 2001; Li et al., 2006; Raghavan et al., 2005;
Woods et al., 2004). In this way, an obvious application of
whole genome platforms in relation to autozygosity is in the
genetic analysis of consanguineous families. This can be
considered as an analogous approach to linkage analysis, in
which researchers aim to define shared regions of autozy-
gosity and/or overlapping structural variants to determine
the role of autozygosity in a particular disease. Autozygos-
ity mapping has long been recognized as a rapid and cost-
effective way to identify loci underlying recessive disease
(Lander and Botstein, 1987) and several genes underlying
different disorders have been identified using this method-
ology (Camargos et al., 2008; Paisan-Ruiz et al., 2009).
Specifically in AD, we have generated the first catalog of
autozygosity in EOAD by studying a consanguineous Israeli
family. Although we were unable to pinpoint a specific gene
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analysis, we were able to generate a catalog that may be
used in future studies of other families (Clarimon et al.,
2008).
Furthermore, even in outbred populations, more individ-
uals have a high frequency of these autozygous tracts than
previously expected (Gibson et al., 2006; Li et al., 2006).
Our group and others have recently reported the unexpected
high degree of apparent parental consanguinity in control
individuals from North America (10% of studied individ-
uals harboring homozygous tracts larger than 5 Mb) (Si-
mon-Sanchez et al., 2007). Similar numbers (6%) were
presented by Li and collaborators, when studying an out-
bred population of unrelated Han Chinese (Li et al., 2006)
and by Gibson et al. who reported that  1,000 tracts
exceeding 1 Mb in length were observed in the 200
unrelated HapMap individuals studied (Gibson et al., 2006).
These observations prompted us to study autozygosity in
LOAD in an outbred population. By comparing measures of
extended homozygosity (greater than 1 Mb in length) in a
population of  800 LOAD cases and  550 controls we
ere able to identify one homozygous region on chromo-
ome 8 (8p12, not including the CLU locus), significantly
ssociated with LOAD. Additionally, the comparison of the
otal numbers of homozygous runs and the total length of
hese runs between cases and controls, revealed a suggestive
ifference in these measures (p-values 0.052–0.062), most
ikely symptomatic of a recessive component in the etiology
f LOAD (Nalls et al., 2009). The role of recessive muta-
ions in AD has been considerably overlooked: in addition
o the recent works describing recessive APP mutations
(discussed above in this review) (Di Fede et al., 2009;
Tomiyama et al., 2008), only two other studies of isolated
populations with a high incidence of the disease have been
reported where the primary analyses were performed using
dominant or additive modes of inheritance (Farrer et al.,
2003; Liu et al., 2007). The new technologies now available
will allow us to overcome this gap soon.
5. The next steps
Two major and clearly nonexclusive pathways have been
recently discussed as the future guidelines in the genome
wide analysis of complex disorders (Goldstein, 2009;
Hirschhorn, 2009; Kraft and Hunter, 2009). The first is the
extension of the assembly of studies containing larger (tens
or even hundreds of thousands) and representative samples
to identify variants with lower frequencies that may have
been missed until now and that could explain the so elusive
fractions of “missing heritability” in AD. The increase in
the number of studied samples will inevitably result in the
discovery of new variants and probably new genes associ-
ated with AD, but the real net value of these variants is
highly disputable. Therefore, the actual dilemma now is to
know how far one should take these studies to keep apositive balance between the resources applied and the
gathered genetic returns (Goldstein, 2009; Hardy and Sin-
gleton, 2009). Clearly, still to discover rare variants and
variants with small effect sizes will be difficult to replicate,
due to reduced power and restriction to specific populations,
respectively. Nonetheless, to identify these rare variants one
may speculate the need to use new chips with a better
coverage of rare variants and the resequencing of previously
identified regions. One may also predict that, being AD a
complex disorder, more emphasis will be put in the study of
endophenotypes, as happened in the study by Liu et al. that
used cognitive function as an endophenotype of AD and
identified the RGSL2, RALGPS2 and C1orf49 genes as
potential causative genes located in one of the associated
genomic regions (Liu et al., 2007). This approach will
obviously require precise and clearly defined clinical assess-
ments.
The second line of investigation will rely in the sequenc-
ing of whole exomes and whole genomes, expectantly un-
veiling several new rarer risk variants. These higher risk
variants may be related to the commoner lower risk variants
found with GWAS. In fact, a classical example comes from
the study of Parkinson’s disease genetics: rare high-risk
variants in the -synuclein gene are the cause of monogenic
PD (Polymeropoulos et al., 1997), while a common haplo-
type of this same gene has been established as a moderate
risk cause of sporadic disease (Simon-Sanchez et al., 2009).
Both lines of research will be followed by large rese-
quencing efforts, to identify the real risk variants. Many
GWAS have identified regions of the genome associated
with AD, but in many cases the real risk/causal changes are
not known. Additionally, in the cases where SNPs have
been associated with a disease, these SNPs identified may in
fact be in LD with the real variants causing the association.
Further functional data, (for instance, the effects of a deter-
mined variant in gene expression), although not always
possible to obtain, will be essential not only to validate the
previously identified variants, but also because many vari-
ants map to noncoding protein sequences, gene deserts, or
genomic regions without any functional elements. The in-
tegration of these functional studies with information on
multiple variants from the same gene, in different popula-
tions and the effects of epigenetics and epistasis will be
vital. The interpretation of these results, however, will be
complex and will most likely require the combination of
disciplines as integrative genomics and systems biology.
Although difficult, this approach will ultimately allow a
more profound understanding of the molecular pathways
underlying AD and AD risk, as well as the subsequent
identification of effective biomarkers and drugs.
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